← Back to headlines
Analysts Project 16% Upside and Strong Buy Rating for BMY Stock
Analysts are recommending Bristol Myers Squibb (BMY) stock as a strong buy, forecasting a potential 16% upside for investors.
20 Apr, 14:50 — 20 Apr, 14:50
Sources
Showing 1 of 1 sources
